Table I.

Specificity of Protection from EAE After Injection with Myelin-derived Sulfatide a

TreatmentMOG35-55/CFA/PTIncidence
 (no. of mice [maximum score])Mean maximum scoreMean day of onset
C57BL/6
PBS+24/24
 [2(2), 7(3), 12(4), 3(5)]3.712.9
Sulfatide (d 0)+13/23b[10(0), 8(2), 1(3), 1(4)]1.818
Sulfatide (d − 7)+4/6
 [1(2), 3(3)]1.915.4
Sulfatide (d + 7)+2/6
 [2(2)]0.716.1
GM1+11/11
 [2(2), 5(3), 4(4)]3.216
Sphingomyelin+4/4
 [2(2), 2(4)]3.013.3
β-GalCer+6/6
 [1(2), 1(3), 2(4), 2(5)]4.014.3
Sulfatide0/5
C57BL/6 – CD1dKO
PBS+7/7
 [2(2), 2(3), 2(4), 1(5)]2.913
Sulfatide+8/8
 [1(2), 3(3), 3(4)]3.012.8
  • a Groups of mice were injected i.p. with 20 μg of sulfatide, mono-GM1, sphingomyelin, β-GalCer, or PBS/vehicle only. On the same day (d 0), injected mice were immunized s.c. with MOG35-55/CFA/PT for the induction of EAE. Sulfatide was also injected either 7 d prior to (d − 7) or after (d + 7) the immunization with MOG35-55/CFA/PT. The incidence, mean maximum score, and mean day of onset of clinical EAE is shown.

  • b P < 0.0001.